In one paragraphTrial report in Anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Jeffry FlorianDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0009-0000-1984-8026 Dro KeshishiDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0009-0007-9447-7000 Victoria GershunyDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0001-9501-666 Pablo SalcedoDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0002-1119-7596 Rutger van der SchrierAnesthesia & Pain Research Unit, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-1422-3830 Keith BurkhartDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0001-8107-4818 Aanchal ShahDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0009-0008-3116-0783 Rebecca RaczDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0002-5487-5692 Vikram PatelDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Ryan DePalmaDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Murali MattaDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0002-0333-5020 Giri VegesnaDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Cheng-Hui HsiaoDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0001-9125-8290 Rodney RouseDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0003-0463-9699 Melanie FeinSpaulding Clinical Research, West Bend, Wisconsin.
Marc StoneDivision of Psychiatry, Office of Neuroscience, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Albert DahanMediD Consultancy, Amsterdam, The Netherlands; Center for Human Drug Research, Leiden, The Netherlands.ORCID 0000-0003-3161-3945 David G StraussDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundOpioid-induced respiratory depression remains a critical public safety concern. Previous clinical findings demonstrated decreased hypercapnic ventilation after 5 days when paroxetine, a selective serotonin reuptake inhibitor (SSRI), was administered alone or with oxycodone. However, uncertainty remained whether chronic use of SSRIs could cause similar respiratory effects. This study investigated whether chronic use of paroxetine and another SSRI, escitalopram, led to a similar decrease in ventilatory response to hypercapnia.
methodsIn this randomized, double-blind, three-period crossover trial, healthy participants were administered one of the following: 40 mg paroxetine from days 1 to 6 and 60 mg from days 7 to 21, 20 mg escitalopram from days 1 to 6 and 30 mg from days 7 to 21, and placebo from days 1 to 21. A dose of 10 mg oxycodone was coadministered on days 6, 12, and 21. Hyperoxic-hypercapnic ventilation was measured using Duffin's rebreathing.
resultsOf the 27 participants, 22 (81%) completed the trial. Paroxetine and escitalopram both significantly decreased hyperoxic-hypercapnic ventilation when coadministered with oxycodone compared to oxycodone alone on day 21 (paroxetine mean difference, -6.5 l/min; one-sided 97.5% CI, -∞ to -3.1; P < 0.001; escitalopram mean difference, -5.5 l/min; one-sided 97.5% CI, -∞ to -2.1; P = 0.001) and when administered alone compared to placebo on day 20 (paroxetine mean difference, -6.5 l/min; one-sided 97.5% CI, -∞ to -2.1; P = 0.003; escitalopram mean difference, -6.9 l/min; one-sided 97.5% CI, -∞ to -2.5; P = 0.002).
conclusionsBoth paroxetine and escitalopram, alone and coadministered with oxycodone, decrease hypercapnic ventilation after 21 days, suggesting that SSRIs may have a class effect on hypercapnic ventilation that persists with chronic use.
Indexed as
Analgesics, OpioidEscitalopramHypercapniaOxycodoneParoxetinePulmonary VentilationSelective Serotonin Reuptake InhibitorsAdultCross-Over StudiesDouble-Blind MethodDrug Therapy, CombinationFemaleHumansMaleYoung AdultAnalgesics, OpioidEscitalopramOxycodoneParoxetineSelective Serotonin Reuptake Inhibitors
Identifiers
PMID41849255
PMCPMC13245928
What OpenQuestion holds
Textmetadata
Read underepoch 390